首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Preclinical characterization and antitumor efficacy of DS-6051b, a novel, orally available small molecule tyrosine kinase inhibitor of ROS1 and NTRKs

【24h】

Preclinical characterization and antitumor efficacy of DS-6051b, a novel, orally available small molecule tyrosine kinase inhibitor of ROS1 and NTRKs

机译：DS-6051b（一种新型的口服小分子ROS1和NTRKs酪氨酸激酶抑制剂）的临床前表征和抗肿瘤功效

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共2页
作者
Kiga M.; Iwasaki S.; Togashi N.; Takeda Y.; Kagoshima Y.; Kanai K.; Kamai Y.; Tominaga Y.; Isoyama T.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Preclinical characterization and antitumor efficacy of DS-6051b, a novel, orally available small molecule tyrosine kinase inhibitor of ROS1 and NTRKs [J] . Kiga M., Iwasaki S., Togashi N., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：DS-6051b（一种新型的口服小分子ROS1和NTRKs酪氨酸激酶抑制剂）的临床前表征和抗肿瘤功效
2. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors [J] . Dazhi Liu, Michael Offin, Stephen Harnicar, Therapeutics and Clinical Risk Management . 2018,第2期

机译：Entrectinib：口服可用的选择性酪氨酸激酶抑制剂，用于治疗NTRK，ROS1和ALK融合阳性实体瘤
3. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 [J] . Tanaka Hidekazu, Hirata Michinari, Shinonome Satomi, Cancer science. . 2014,第8期

机译：表皮生长因子受体和人表皮生长因子受体2的口服可逆酪氨酸激酶抑制剂S-222611的临床前抗肿瘤活性
4. Identification and Characterization of Synthetic Peptide Substrates and Small Molecule Inhibitors of Non Receptor Tyrosine Kinase Etk [C] . Lauren Lee, Ruiwu Liu, Nianhuan Yao American Peptide Symposium . 2006

机译：非受体酪氨酸激酶ETK的合成肽底物和小分子抑制剂的鉴定与表征
5. Changing the Drug Exposure of Small Molecule Tyrosine Kinase Inhibitors. [D] . Yago, Marc Anthony R. 2015

机译：改变小分子酪氨酸激酶抑制剂的药物暴露。
6. Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation [O] . Ramesh Narayanan, Muralimohan Yepuru, Christopher C. Coss, -1

机译：新型小分子TRK和ROS1酪氨酸激酶抑制剂用于癌症和炎症的发现和临床前表征
7. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation. [O] . Ramesh Narayanan, Muralimohan Yepuru, Christopher C Coss, 2013

机译：用于治疗癌症和炎症的新型小分子TRK和ROs1酪氨酸激酶抑制剂的发现和临床前特征。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号